Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on March 7.
David Risinger has given his Hold rating due to a combination of factors regarding Pfizer’s ongoing and future projects. One of the primary considerations is the status of Pfizer’s research and development, particularly the once-daily oral GLP-1 danuglipron, which is currently under multiple formulation evaluations with a decision expected in the summer. Other aspects include the advancement of a small-molecule obesity drug into Phase 2 development, the potential of a fourth-generation pneumococcal conjugate vaccine with broader serotype coverage, and the development of a second-generation modified flu vaccine with enhanced immunogenicity against Influenza B, with anticipated data and launch in the coming years.
Furthermore, while Pfizer is showing promise with its pipeline, including enthusiasm for cancer cachexia treatment opportunities and the progression of multiple oral obesity assets, there are still uncertainties and timelines that must be met before these developments can significantly impact the company’s growth. The lack of specific details on the new mechanisms behind some of these assets, such as the undisclosed mechanism for the obesity drug, also contributes to the cautious stance. These factors, combined with the need for successful clinical trial outcomes and regulatory approvals, suggest a level of prudent optimism, which is reflected in Risinger’s Hold rating for Pfizer’s stock.
In another report released on March 7, J.P. Morgan also maintained a Hold rating on the stock with a $30.00 price target.
PFE’s price has also changed moderately for the past six months – from $34.070 to $27.940, which is a -17.99% drop .
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Pfizer (PFE) Company Description:
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Novavax (NASDAQ:NVAX): A Highly Speculative Value Trade in the Post-Pandemic Era
- Pfizer to Offload Haleon Shares Worth $2.5B
- Caribou Biosciences (NASDAQ:CRBU): Recent Price Volatility May Offer Investors an Entry Point
- Pfizer announces EC grants marketing authorization for Prevenar 20
- Oric Pharmaceuticals price target raised to $17 from $14 at Oppenheimer
